Watchful waiting for prostate cancer: a review article.

Abstract:

:As earlier detection of prostate cancer increases because of prostate-specific antigen (PSA) testing, appropriate use for watchful waiting warrants re-evaluation. We have drawn together the significant watchful waiting literature and used it to evaluate the use of watchful waiting in the PSA era. We conducted literature searches for studies examining outcomes of watchful waiting and examined new literature emerging about the use of PSA for the follow-up of watchful waiting patients. Watchful waiting has the potential to play an increasingly important role in prostate cancer as less advanced disease is detected and methods are refined for identifying low-risk patients.

authors

Chodak GW,Warren KS

doi

10.1038/sj.pcan.4500857

subject

Has Abstract

pub_date

2006-01-01 00:00:00

pages

25-9

issue

1

eissn

1365-7852

issn

1476-5608

pii

4500857

journal_volume

9

pub_type

杂志文章,评审
  • Diabetes and prostate cancer risk in the REDUCE trial.

    abstract::Men with diabetes mellitus are less likely to be diagnosed with prostate cancer (PCa). As diabetic men have lower serum PSA, it is unclear if this is due to lower PCa incidence or reflects detection bias from fewer PSA-triggered biopsies. To account for differential biopsy rates, we used multivariate regression to exa...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2011.28

    authors: Wu C,Moreira DM,Gerber L,Rittmaster RS,Andriole GL,Freedland SJ

    更新日期:2011-12-01 00:00:00

  • Frequency of impalpable prostate adenocarcinoma and precancerous conditions in Greek male population: an autopsy study.

    abstract::A series of 212 prostate specimens of men dead between August 2002-August 2004, have been sectioned in consecutive autopsies and subjected to whole mount analysis in purpose to determine the epidemiology of impalpable prostate cancer in Greece. Impalpable prostate carcinomas were found in 40 cases (18.8%) most in the ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500847

    authors: Stamatiou K,Alevizos A,Perimeni D,Sofras F,Agapitos E

    更新日期:2006-01-01 00:00:00

  • Novel role for the transient receptor potential channel TRPM2 in prostate cancer cell proliferation.

    abstract::We have identified a novel function for a member of the transient receptor potential (TRP) protein super-family, TRPM2, in prostate cancer cell proliferation. TRPM2 encodes a non-selective cation-permeable ion channel. We found that selectively knocking down TRPM2 with the small interfering RNA technique inhibited the...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2009.55

    authors: Zeng X,Sikka SC,Huang L,Sun C,Xu C,Jia D,Abdel-Mageed AB,Pottle JE,Taylor JT,Li M

    更新日期:2010-06-01 00:00:00

  • Prevalence of prostatic intra-epithelial neoplasia (PIN) in biopsies from hospital practice and pilot screening: clinical implications.

    abstract::As high grade PIN is commonly associated with concomitant cancer, current literature recommends re-biopsy of patients with high grade PIN. This paper describes the prevalence of high grade prostatic intra-epithelial neoplasia (PIN) from three independent clinical settings, reported by a single pathologist (MCP). High ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500210

    authors: Feneley MR,Green JS,Young MP,Bose P,Kirby RS,Peeling WB,Parkinson MC

    更新日期:1997-12-01 00:00:00

  • 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.

    abstract::This literature review discusses the theoretical background of 5alpha-reductase inhibitor (5ARI) treatment and the resulting clinical implications. A Medline-based search for peer-reviewed articles addressing 5ARIs, benign prostatic hyperplasia and prostate cancer was performed. The 5ARIs Finasteride and Dutasteride, ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/pcan.2008.56

    authors: Dörsam J,Altwein J

    更新日期:2009-01-01 00:00:00

  • SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design.

    abstract::Prostate cancer is the commonest non-skin malignancy in the United States and has a substantial mortality rate despite the use of PSA-based screening. Furthermore, therapy for prostate cancer by surgery, radiotherapy or hormonal manipulation carries a significant risk of treatment-related morbidity. Recent analysis of...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500412

    authors: Klein EA,Thompson IM,Lippman SM,Goodman PJ,Albanes D,Taylor PR,Coltman C

    更新日期:2000-11-01 00:00:00

  • A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.

    abstract:BACKGROUND:Intermittent androgen suppression (IAS) is an increasingly popular treatment option for castrate-sensitive prostate cancer. On the basis of previous data with anti-angiogenic strategies, we hypothesized that pan-inhibition of the vascular endothelial growth factor receptor using pazopanib during the IAS off ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/pcan.2011.49

    authors: Ward JE,Karrison T,Chatta G,Hussain M,Shevrin D,Szmulewitz RZ,O'Donnell PH,Stadler WM,Posadas EM

    更新日期:2012-03-01 00:00:00

  • Transrectal ultrasound imaging of the prostate: review and perspectives of recent developments.

    abstract::We present a critical review of the recent literature and discuss the development and prospective view of the evaluations of transrectal ultrasound with regard to prostate malignancy. We illustrate this with personal experiences. Material and Methods: Based on a critical evaluation of clinical data we address the appa...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500326

    authors: Sedelaar JP,De La Rosette JJ,Beerlage HP,Wijkstra H,Debruyne FM,Aarnink RG

    更新日期:1999-12-01 00:00:00

  • Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer.

    abstract:BACKGROUND:The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-020-0224-4

    authors: Du M,Tian Y,Tan W,Wang L,Wang L,Kilari D,Huang CC,Wang L,Kohli M

    更新日期:2020-12-01 00:00:00

  • Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients.

    abstract:INTRODUCTION:Approximately 85% of patients who die from prostate cancer present the spread of bone metastases. Even though the radiological appearance of such metastases is osteoblastic, it is now known that these lesions coexist in their microenvironment with blastic and lytic lesions. The process always begins with b...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500752

    authors: Rodrigues P,Hering F,Campagnari JC

    更新日期:2004-01-01 00:00:00

  • Association between metabolic syndrome, diabetes mellitus and prostate cancer risk.

    abstract:BACKGROUND:The worldwide incidence of diabetes mellitus is rapidly increasing. There is recent interest in the influence of glucose metabolism on oncogenesis. We investigated the role of diabetes mellitus and the metabolic syndrome (MS) on prostate cancer development. METHODS:This study consisted of 11 541 men with co...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2012.54

    authors: Lawrence YR,Morag O,Benderly M,Boyko V,Novikov I,Dicker AP,Goldbourt U,Behar S,Barchana M,Wolf I

    更新日期:2013-06-01 00:00:00

  • The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer.

    abstract:OBJECTIVE:To determine whether the duration of the off-treatment interval in patients being treated with intermittent androgen deprivation therapy can be predicted by the length of the CAG trinucleotide repeat polymorphism in the androgen receptor. METHODS:This is a companion study to a prospective randomized trial, N...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.pcan.4500792

    authors: Klotz L,Correia A,Zhang W

    更新日期:2005-01-01 00:00:00

  • Stromal-epithelial measurements of prostate cancer in native Japanese and Japanese-American men.

    abstract::We measured the histologic stromal and epithelial tissue components of the benign (normal) and malignant tissue compartments of Japanese-Americans (J-A) and native Japanese (NJ) men living in Japan. The patient cohort included 25 NJ men undergoing radical prostatectomy (RP) in Nagoya, Japan and 25 J-A (second or third...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500738

    authors: Veltri RW,Park J,Miller MC,Marks L,Kojima M,van Rootselaar C,Khan MA,Partin AW

    更新日期:2004-01-01 00:00:00

  • The relationship between quality and costs: factors that affect the hospital costs of radical prostatectomy.

    abstract::The present study seeks to establish a relationship between the quality of a surgical procedure and the subsequent hospital costs for that procedure by investigating the influence of both patient and peri-operative factors on the hospital costs of radical prostatectomy. All men who underwent radical prostatectomy at o...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500529

    authors: Benoit RM,Cohen JK

    更新日期:2001-01-01 00:00:00

  • Distribution of vascular endothelial growth factor (VEGF) in prostate disease.

    abstract::Vascular endothelial growth factor (VEGF) is a heparin-binding polypeptide growth factor. It is a potent mitogen for endothelial cells. Immunohistochemical localisation of VEGF was performed on 25 moderate to poorly differentiated stage T4 M+ prostate cancer specimens and 30 benign prostatic hyperplasia (BPH) specimen...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500575

    authors: Walsh K,Sriprasad S,Hopster D,Codd J,Mulvin D

    更新日期:2002-01-01 00:00:00

  • The effect of exercise training on cardiometabolic health in men with prostate cancer receiving androgen deprivation therapy: a systematic review and meta-analysis.

    abstract:BACKGROUND:Growing evidence suggests that men exposed to androgen deprivation therapy (ADT) have an increased risk of cardiovascular disease. While exercise has shown to attenuate some adverse effects of ADT, the effects on cardiometabolic health have not been systematically evaluated. OBJECTIVE:To evaluate the effect...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/s41391-020-00273-5

    authors: Bigaran A,Zopf E,Gardner J,La Gerche A,Murphy DG,Howden EJ,Baker MK,Cormie P

    更新日期:2020-08-28 00:00:00

  • Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer.

    abstract:BACKGROUND:To evaluate the safety and clinical feasibility of focal irreversible electroporation (IRE) of the prostate. METHODS:We assessed the toxicity profile and functional outcomes of consecutive patients undergoing focal IRE for localised prostate cancer in two centres. Eligibility was assessed by multi-parametri...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2014.33

    authors: Valerio M,Stricker PD,Ahmed HU,Dickinson L,Ponsky L,Shnier R,Allen C,Emberton M

    更新日期:2014-12-01 00:00:00

  • Androgen receptor antigen density and S-phase fraction in prostate cancer: a pilot study.

    abstract:PURPOSE:To determine whether quantitative flow cytometric androgen receptor density expression (MFC ratio) in prostate cancer was associated with S-phase fraction. METHODS:Flow cytometry was performed to determine DNA aneuploidy, S-phase fraction, percentage of androgen receptor (AR)-positive cells, and MFC ratio in p...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500672

    authors: Abdel-Wahab M,Krishan A,Milikowski C,Wahab AA,Walker G,Markoe A

    更新日期:2003-01-01 00:00:00

  • Gene delivery into prostate cancer cells by holmium laser application.

    abstract::New approaches to treat prostate cancer (PCA) are utilizing gene therapy and aim to correct the disease at the genetic level. Getting a gene efficiently into the target cell is the subject of much interest. We used a holmium laser for transfecting rat PCA cells with the reporter gene pEGFP. By FACS analysis and fluore...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500653

    authors: Sagi S,Knoll T,Trojan L,Schaaf A,Alken P,Michel MS

    更新日期:2003-01-01 00:00:00

  • Patient-reported quality of life progression in men with prostate cancer following primary cryotherapy, cyberknife, or active holistic surveillance.

    abstract:BACKGROUND:Technological advancements have led to the success of minimally invasive treatment modalities for prostate cancer such as CyberKnife and Cryotherapy. Here, we investigate patient-reported urinary function, bowel habits, and sexual function in patients following CyberKnife (CK) or Cryotherapy treatment, and c...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-017-0004-y

    authors: Werneburg GT,Kongnyuy M,Halpern DM,Salcedo JM,Kosinski KE,Haas JA,Schiff JT,Corcoran AT,Katz AE

    更新日期:2018-09-01 00:00:00

  • The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.

    abstract::The purpose of this study was to evaluate the relationship of baseline body mass index (BMI) and serum testosterone level with prostate cancer outcomes in men with castration-resistant metastatic prostate cancer (CRPC). BMI and testosterone levels were evaluated for their ability to predict overall survival (OS) and p...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2008.36

    authors: Armstrong AJ,Halabi S,de Wit R,Tannock IF,Eisenberger M

    更新日期:2009-01-01 00:00:00

  • Treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction in real life practice in France.

    abstract::The objective of this work is to describe the profile of prevalent and incident populations suffering from lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) and to analyse the management of care by 620 general practitioners (GPs) in France in 1997 and 1998. Patient records were extra...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500517

    authors: Vallancien G,Pariente P

    更新日期:2001-01-01 00:00:00

  • Contemporary management of men with high-risk localized prostate cancer in the United States.

    abstract::This corrects the article DOI: 10.1038/pcan.2017.5. ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,已发布勘误

    doi:10.1038/pcan.2017.35

    authors: Weiner AB,Matulewicz RS,Schaeffer EM,Liauw SL,Feinglass JM,Eggener SE

    更新日期:2017-12-01 00:00:00

  • The prognostic role of tertiary Gleason pattern 5 in a contemporary grading system for prostate cancer.

    abstract:BACKGROUND:Recently, a new prostate cancer (PC) grading system has been introduced, where Gleason score (GS) 7 (3+4) and GS 7 (4+3) are categorized into two separate groups. However, GS 7 with tertiary Gleason pattern 5 (TGP5) was not incorporated in the new grading system. In the present study, we validated the progno...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2016.55

    authors: Jang WS,Yoon CY,Kim MS,Kang DH,Kang YJ,Jeong WS,Abalajon MJ,Ham WS,Choi YD

    更新日期:2017-03-01 00:00:00

  • Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.

    abstract:OBJECTIVE:To determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs)-based prognosis. PATIENTS AND METHODS:A two-cohort-based evaluation for serum CGA for prognostication in C...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/s41391-018-0046-9

    authors: Giridhar KV,Sanhueza C,Hillman DW,Alkhateeb H,Carlson R,Tan W,Costello BA,Quevedo F,Pagliaro L,Kohli M

    更新日期:2018-09-01 00:00:00

  • ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.

    abstract:BACKGROUND:Overexpression of the ERG protein is highly prevalent in prostate cancer (PCa) and commonly results from gene fusions involving the ERG gene. Recently, N-terminal epitope-targeted mouse and a C-terminal epitope-targeted rabbit monoclonal anti-ERG antibody (ERG-MAbs) have been introduced for the detection of ...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2011.67

    authors: Braun M,Goltz D,Shaikhibrahim Z,Vogel W,Böhm D,Scheble V,Sotlar K,Fend F,Tan SH,Dobi A,Kristiansen G,Wernert N,Perner S

    更新日期:2012-06-01 00:00:00

  • The role of candidate genetic polymorphisms in the etiology of prostate cancer.

    abstract::Prostate cancer appears to result from complex interactions among genetic, endocrine and environmental factors. Identification of risk factors for development and progression of prostate cancer is needed. This will allow researchers to design strategies to reduce the morbidity and mortality from this cancer and to ide...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500471

    authors: Neuhausen SL

    更新日期:2000-12-01 00:00:00

  • TGFBR1*6A is not associated with prostate cancer in men of European ancestry.

    abstract::The TGFBR1*6A (*6A) variant in exon 1 of the TGFBR1 gene has been postulated as a putative tumor susceptibility allele in several studies. We have performed a case-control study in 537 men with histologically verified prostate cancer and in 488 unrelated controls to investigate the association of *6A with prostate can...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/sj.pcan.4500765

    authors: Suarez BK,Pal P,Jin CH,Kaushal R,Sun G,Jin L,Pasche B,Deka R,Catalona WJ

    更新日期:2005-01-01 00:00:00

  • Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.

    abstract:BACKGROUND:The lack of sensitive and specific biomarkers for prostate cancer (PCa) has led to over-diagnosis and overtreatment with uncertain benefit. Therefore, biomarkers for early diagnosis that can distinguish aggressive from indolent tumors and that can detect metastatic or recurrent disease are needed. Long nonco...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章,评审

    doi:10.1038/pcan.2015.48

    authors: Mouraviev V,Lee B,Patel V,Albala D,Johansen TE,Partin A,Ross A,Perera RJ

    更新日期:2016-03-01 00:00:00

  • Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy.

    abstract::Chronic fatigue (CF) is a distressing symptom that follows cancer treatment; however, it has rarely been studied in hormone-naïve prostate cancer survivors after radical prostatectomy (RP) or definitive radiotherapy (RAD). We investigated CF in prostate cancer survivors after RP or RAD as monotherapy and explored asso...

    journal_title:Prostate cancer and prostatic diseases

    pub_type: 杂志文章

    doi:10.1038/pcan.2009.61

    authors: Kyrdalen AE,Dahl AA,Hernes E,Cvancarova M,Fosså SD

    更新日期:2010-06-01 00:00:00